J.W. Cole Advisors Inc. Has $810,000 Stock Position in Boston Scientific Corporation (NYSE:BSX)

J.W. Cole Advisors Inc. boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 60.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,031 shares of the medical equipment provider's stock after acquiring an additional 3,032 shares during the period. J.W. Cole Advisors Inc.'s holdings in Boston Scientific were worth $810,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares during the period. Bank Pictet & Cie Europe AG grew its stake in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the period. Highview Capital Management LLC DE grew its stake in shares of Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after purchasing an additional 1,439 shares during the period. Modern Wealth Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $269,000. Finally, FineMark National Bank & Trust bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $206,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.1%

Shares of NYSE BSX traded down $0.14 during mid-day trading on Friday, hitting $106.07. The company had a trading volume of 5,875,124 shares, compared to its average volume of 7,847,640. The company has a market capitalization of $156.92 billion, a PE ratio of 63.14, a price-to-earnings-growth ratio of 2.67 and a beta of 0.68. The firm has a 50-day simple moving average of $103.58 and a two-hundred day simple moving average of $101.51. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company posted $0.62 earnings per share. Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president owned 18,705 shares of the company's stock, valued at $1,955,420.70. This trade represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 457,144 shares of company stock valued at $47,296,288. 0.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research analyst reports. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Evercore ISI increased their price target on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Royal Bank Of Canada increased their price target on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Two research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.